Detalhe da pesquisa
1.
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Blood
; 142(20): 1697-1707, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595359
2.
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol
; 200(5): 573-578, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413792
3.
The Duffy-null genotype and risk of infection.
Hum Mol Genet
; 29(20): 3341-3349, 2020 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32959868
4.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Blood
; 135(9): 680-688, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932839
5.
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Br J Haematol
; 193(1): 155-159, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32996123
6.
A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.
Mol Psychiatry
; 24(3): 328-337, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30647433
7.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood
; 129(9): 1143-1154, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872058
8.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Blood
; 130(17): 1889-1897, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074595
9.
Leukocytapheresis in the management of adults with acute myeloid leukaemia: A survey of AML treating centres highlighting variability in practice.
Transfus Med
; 33(2): 181-187, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260030
10.
Telomere length is an independent prognostic marker in MDS but not in de novo AML.
Br J Haematol
; 178(2): 240-249, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28486748
11.
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Br J Haematol
; 170(1): 29-39, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25824940
12.
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Blood
; 122(8): 1384-94, 2013 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23838349
13.
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.
Br J Haematol
; 184(2): 161-175, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30426472
14.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
J Clin Oncol
; 42(10): 1158-1168, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215358
15.
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Blood Adv
; 8(2): 343-352, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039513
16.
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Br J Haematol
; 161(1): 57-67, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23356405
17.
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Br J Haematol
; 162(4): 498-508, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23758082
18.
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Blood
; 117(12): 3286-93, 2011 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21263155
19.
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Nat Commun
; 14(1): 7725, 2023 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001082
20.
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
J Clin Oncol
; 41(19): 3534-3544, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37126762